Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.

摘要: Purpose This analysis from Avastin® Registries: Investigation of Effectiveness and Safety (ARIES) examined the association between exposure to bevacizumab after disease progression (PD) postprogression survival (PPS) in bevacizumab-exposed metastatic colorectal cancer (mCRC) through application time-dependent time-fixed analytical methods. Methods Patients with mCRC who were treated first-line survived first PD (PD1) included. A Cox regression model was fitted assess effect cumulative on PPS, while controlling for potential confounders. In addition support findings previous studies, a modified intent-to-treat (mITT) compared PPS patients received beyond (BBP) those did not (No-BBP). Results Of 1550 patients, 1199 PD1 had median 13.4 months. Cumulative associated improved (p = 0.0040). After adjusting confounders, hazard ratios (HRs) decreased, average, by 1.2% (range, 1.1–1.3%) each additional dose bevacizumab. mITT analysis, BBP (n = 438) 14.4 months vs 10.6 months No-BBP (n = 667). found be independently longer multivariable (HR, 0.84; 95% confidence interval, 0.73–0.97). Protocol-specified adverse events suspected occurred 13.0% BBP. Conclusion This supports observation that is mCRC. Copyright © 2014 John Wiley & Sons, Ltd.